Skip to content


Scintimun (besilesomab) is an antibody pharmaceutical. Besilesomab was first approved as Scintimun on 2010-01-11. It has been approved in Europe to treat osteomyelitis and radionuclide imaging.
Trade Name Scintimun
Common Name Besilesomab
Indication osteomyelitis, radionuclide imaging
Drug Class Monoclonal antibodies: infix for inflammatory/infectious lesions|monoclonal antibodies: mouse, bone target
Get full access now